Yi-Te Lee1,2, Amit G Singal3, Marie Lauzon4, Vatche G Agopian5,6, Michael Luu4, Mazen Noureddin7,8, Tsuyoshi Todo8, Irene K Kim8, Marc L Friedman9, Kambiz Kosari8, Nicholas N Nissen8,10, Lewis R Roberts11, Julie K Heimbach12, Gregory J Gores11, Ju Dong Yang7,8,10. 1. California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, California, USA. 2. Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California, USA. 3. Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 4. Biostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, California, USA. 5. Department of Surgery, University of California, Los Angeles, Los Angeles, California, USA. 6. Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California, USA. 7. Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA. 8. Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA. 9. Department of Radiology, Cedars-Sinai Medical Center, Los Angeles, California, USA. 10. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. 11. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. 12. Division of Transplant Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
BACKGROUND: Curative surgical treatments afford the best prognosis for patients with intrahepatic cholangiocarcinoma (iCCA); however, the comparative effectiveness of treatment options and factors associated with curative treatment receipt for early stage iCCA remain unknown. METHODS: The authors identified patients who were diagnosed with early stage iCCA, defined as a unifocal tumor <3 cm, during 2004-2018 from the National Cancer Database. Multivariable logistic and Cox regression analyses were used to identify the factors associated with curative treatment and overall survival (OS), respectively. RESULTS: The proportion of patients with early stage iCCA increased from 4.5% in 2004 to 7.3% in 2018, with the odds of early stage detection increasing by 3.1% per year (odds ratio [OR], 1.031; 95% CI, 1.015-1.049). Of 1093 patients who had early stage iCCA, 464 (42.5%) underwent resection, 113 (10.3%) underwent ablation, 62 (5.7%) underwent liver transplantation, and 454 (41.5%) received noncurative treatments. Hispanic patients (adjusted OR [aOR], 0.57; 95% CI, 0.33-0.97) and Black patients (aOR, 0.47; 95% CI, 0.28-0.77) were less likely to receive curative treatments than White patients. Compared with patients who underwent surgical resection, those who underwent liver transplantation had a trend toward improved OS (adjusted hazard ratio [aHR], 0.63; 95% CI, 0.37-1.08), whereas those who underwent local ablation (aHR, 1.39; 95% CI, 1.01-1.92) and noncurative treatments (aHR, 3.97; 95% CI, 3.24-4.88) experienced worse OS. CONCLUSIONS: More than one third of patients with early stage iCCA did not receive curative treatment, with Hispanic and Black patients being less likely to receive curative treatments than White patients. Surgical resection and liver transplantation were associated with improved survival compared with local ablation. Future studies should investigate disparities in curative treatment receipt and outcomes for early stage iCCA.
BACKGROUND: Curative surgical treatments afford the best prognosis for patients with intrahepatic cholangiocarcinoma (iCCA); however, the comparative effectiveness of treatment options and factors associated with curative treatment receipt for early stage iCCA remain unknown. METHODS: The authors identified patients who were diagnosed with early stage iCCA, defined as a unifocal tumor <3 cm, during 2004-2018 from the National Cancer Database. Multivariable logistic and Cox regression analyses were used to identify the factors associated with curative treatment and overall survival (OS), respectively. RESULTS: The proportion of patients with early stage iCCA increased from 4.5% in 2004 to 7.3% in 2018, with the odds of early stage detection increasing by 3.1% per year (odds ratio [OR], 1.031; 95% CI, 1.015-1.049). Of 1093 patients who had early stage iCCA, 464 (42.5%) underwent resection, 113 (10.3%) underwent ablation, 62 (5.7%) underwent liver transplantation, and 454 (41.5%) received noncurative treatments. Hispanic patients (adjusted OR [aOR], 0.57; 95% CI, 0.33-0.97) and Black patients (aOR, 0.47; 95% CI, 0.28-0.77) were less likely to receive curative treatments than White patients. Compared with patients who underwent surgical resection, those who underwent liver transplantation had a trend toward improved OS (adjusted hazard ratio [aHR], 0.63; 95% CI, 0.37-1.08), whereas those who underwent local ablation (aHR, 1.39; 95% CI, 1.01-1.92) and noncurative treatments (aHR, 3.97; 95% CI, 3.24-4.88) experienced worse OS. CONCLUSIONS: More than one third of patients with early stage iCCA did not receive curative treatment, with Hispanic and Black patients being less likely to receive curative treatments than White patients. Surgical resection and liver transplantation were associated with improved survival compared with local ablation. Future studies should investigate disparities in curative treatment receipt and outcomes for early stage iCCA.
Authors: Mohamed M Gad; Anas M Saad; Mohammed Faisaluddin; Mihnea Alexandru Gaman; Inas A Ruhban; Khalid A Jazieh; Muneer J Al-Husseini; Carlos Roberto Simons-Linares; M Bassam Sonbol; Bassam N Estfan Journal: Clin Res Hepatol Gastroenterol Date: 2020-04-28 Impact factor: 2.947
Authors: Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores Journal: Nat Rev Gastroenterol Hepatol Date: 2020-06-30 Impact factor: 46.802
Authors: Jonathan J Hue; Flavio G Rocha; John B Ammori; Jeffrey M Hardacre; Luke D Rothermel; Kenneth D Chavin; Jordan M Winter; Lee M Ocuin Journal: J Surg Oncol Date: 2021-01-05 Impact factor: 3.454
Authors: G Sapisochin; M Facciuto; L Rubbia-Brandt; J Marti; N Mehta; F Y Yao; E Vibert; D Cherqui; D R Grant; R Hernandez-Alejandro; C H Dale; A Cucchetti; A Pinna; S Hwang; S G Lee; V G Agopian; R W Busuttil; S Rizvi; J K Heimbach; M Montenovo; J Reyes; M Cesaretti; O Soubrane; T Reichman; J Seal; P T W Kim; G Klintmalm; C Sposito; V Mazzaferro; P Dutkowski; P A Clavien; C Toso; P Majno; N Kneteman; C Saunders; J Bruix Journal: Hepatology Date: 2016-08-24 Impact factor: 17.425
Authors: Amit G Singal; Sruthi Patibandla; Joseph Obi; Hannah Fullington; Neehar D Parikh; Adam C Yopp; Jorge A Marrero Journal: Clin Gastroenterol Hepatol Date: 2020-09-10 Impact factor: 13.576